Roche deal, AACR data unveil Vividion’s targeted degradation strategy

With $135 million up front from Roche, Vividion aims to develop more potent, durable and selective targeted protein degraders by using its covalent chemistry to engage untapped ubiquitin ligases.

Targeted protein degraders typically connect one ligand that binds a target of interest to another that binds one of two E3 ubiquitin ligases -- CRBN or vHL; the E3 ligase then tags the target for degradation by the proteasome. Both binding events are non-covalent, and therefore reversible...